At a press conference on Cuban television, Dr. Rolando Ochoa, a researcher with the Finlay Vaccines Institute (IFV) and project leader, explained that Soberana Plus has been designed for convalescents and as reinforcement for those who have been vaccinated with Soberana 02 in its phase III of clinical trials.
'It will be a multicenter, adaptive study in parallel random groups, a double-blind and control study with a placebo,' Ochoa noted.
The study involves patients aged 19-80 who were discharged from hospitals at least two months before receiving a single dose of Soberana Plus.
The Soberana vaccines are produced by the Finlay Institute in partnership with the Centre for Molecular Immunology and the National Biopreparations Centre.
The name Soberana means “sovereign”, reflecting their economic and political importance for the island – without this domestic production, Cuba would struggle to access foreign vaccines either because of their cost in international markets or because of the longstanding US embargo.
These vaccines work by inserting genetic information into superior mammalian cells. Soberana Plus is the first vaccine for convalescent COVID-19 patients to reach the clinical trial stage.
- Countries: Cuba
- Business Planning In A Post-COVID Environment
- CUBA | US is yet to condemn attack on Cuban Embassy
- CARICOM pleas for help but Biden shackeled by deal with Vaccine Makers
- JAMAICA | PNP wants explaination for drastic reduction in COVID-19 PCR Testing
- CUBA | Newsweek addresses challenges in US-Cuba relations